Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 7, 2008 Brian Lawler	PDL Delivers a Dividend The drugmaker's investors get a hefty payout.
The Motley Fool May 22, 2008 Brian Lawler	Enzon Shareholders Steal the Show A shareholder tussle overshadows clinical trial data.
The Motley Fool April 14, 2008 Brian Lawler	PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.
The Motley Fool December 27, 2007 Brian Lawler	Breaking Down a Biotech's Assets Enzon Pharmaceuticals becomes the latest drugmaker to receive interest from a hedge fund.
The Motley Fool May 30, 2008 Brian Lawler	PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs.
The Motley Fool February 6, 2008 Brian Lawler	PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note.
The Motley Fool April 28, 2011 Brian Orelli	Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.
The Motley Fool November 12, 2007 Brian Lawler	What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
The Motley Fool August 29, 2007 Brian Lawler	PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors.
The Motley Fool December 7, 2011 Dan Caplinger	Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders.
The Motley Fool September 26, 2007 Brian Lawler	Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
The Motley Fool December 18, 2007 Brian Lawler	PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note.
The Motley Fool January 26, 2005 Charly Travers	Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock.
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
The Motley Fool August 2, 2007 Brian Lawler	PDL Minds Its Mild Manners The biopharma announces placid second-quarter results -- investors, take note.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion.
The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
The Motley Fool August 5, 2005 Charly Travers	No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders.
The Motley Fool November 6, 2006 Brian Lawler	Mixed Feelings About PDL The biopharmaceutical's third-quarter results look fine on the surface, but does deeper digging reveal some reasons for investors to be concerned?
The Motley Fool September 24, 2007 Brian Lawler	Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool August 21, 2007 Brian Lawler	Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool October 15, 2007 Brian Lawler	PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note.
The Motley Fool May 3, 2005 Charly Travers	PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner.
The Motley Fool October 30, 2007 Brian Lawler	ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results.
The Motley Fool May 26, 2009 Brian Orelli	Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool September 28, 2007 Brian Lawler	Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs.
The Motley Fool April 27, 2007 Brian Lawler	PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool October 13, 2010 Jordan DiPietro	3 Sinking Stocks for Savvy Investors These three socks may be ready to climb.
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool November 19, 2010 Jim Royal	Spinoff Stocks Worth Watching Look at these spinoffs.
The Motley Fool March 16, 2007 Brian Lawler	PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note.
The Motley Fool September 7, 2011 Selena Maranjian	Here's What Seth Klarman Is Buying Seth Klarman founded Baupost Group back in 1982. He sticks to his value-investing principles so diligently that at times, a lack of ready bargains drives him to keep a large chunk of his assets in cash. Here's where the firm is winning and losing now.
The Motley Fool December 4, 2008 Brian Orelli	Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field.
The Motley Fool August 22, 2006 Brian Lawler	Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company.
The Motley Fool April 26, 2007 Brian Lawler	Genzyme Is Good The biopharma giant announced unexpectedly strong first-quarter results on the back of higher sales of recently launched compounds.
The Motley Fool November 2, 2004 Charly Travers	Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth.